{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:05:51Z","timestamp":1791295551347,"version":"4.1.0"},"reference-count":13,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Immature platelets (IPFs), which are hemostatically more active than mature platelets, have been found elevated in essential thrombocythemia and polycythemia vera, 2 myeloproliferative neoplasms (MPN) characterized by an increased risk of thrombosis. It is not known whether the IPF levels are influenced by pathogenetic factors, including JAK2V617F mutational status, or by treatment regimen. To address this point, in 46 essential thrombocythemia and 38 polycythemia vera consecutive patients, we measured IPF and correlated the results to JAK2V617F mutation and myelosuppressive treatment with hydroxyurea. This analysis provides 2 new elements regarding IPF and MPN. The first finding is that the JAK2V617F mutation is linked to the quantity of IPF in patients with MPN, which might contribute to the prothrombotic phenotype in these patients. The second finding is that IPF is susceptible to myelosuppressive treatment, which may additionally explain the favorable effect of hydroxyurea therapy on MPN outcome as well as the associated thrombotic risk.<\/jats:p>","DOI":"10.1182\/blood-2011-02-339655","type":"journal-article","created":{"date-parts":[[2011,7,13]],"date-time":"2011-07-13T05:56:36Z","timestamp":1310536596000},"page":"2599-2601","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":63,"title":["JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients"],"prefix":"10.1182","volume":"118","author":[{"given":"Marina","family":"Panova-Noeva","sequence":"first","affiliation":[{"name":"Division of Immunohematology and Transfusion Medicine, Ospedali Riuniti di Bergamo, Bergamo, Italy;"},{"name":"Department of Biochemistry, Laboratory for Clinical Thrombosis and Hemostasis, Maastricht University, Maastricht, The Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Marchetti","sequence":"additional","affiliation":[{"name":"Division of Immunohematology and Transfusion Medicine, Ospedali Riuniti di Bergamo, Bergamo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Buoro","sequence":"additional","affiliation":[{"name":"Divisions of Laboratory Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Russo","sequence":"additional","affiliation":[{"name":"Division of Immunohematology and Transfusion Medicine, Ospedali Riuniti di Bergamo, Bergamo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Leuzzi","sequence":"additional","affiliation":[{"name":"Division of Immunohematology and Transfusion Medicine, Ospedali Riuniti di Bergamo, Bergamo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Finazzi","sequence":"additional","affiliation":[{"name":"Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[{"name":"Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosimo","family":"Ottomano","sequence":"additional","affiliation":[{"name":"Divisions of Laboratory Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"ten Cate","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Laboratory for Clinical Thrombosis and Hemostasis, Maastricht University, Maastricht, The Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Falanga","sequence":"additional","affiliation":[{"name":"Division of Immunohematology and Transfusion Medicine, Ospedali Riuniti di Bergamo, Bergamo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6","key":"2019111808435200100_B1","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/09537109777050","article-title":"Reticulated platelets.","volume":"8","author":"Harrison","year":"1997","journal-title":"Platelets"},{"issue":"4","key":"2019111808435200100_B2","first-page":"267","article-title":"Reticulated platelets\u2013automated measurement and clinical utility.","volume":"36","author":"Watanabe","year":"1995","journal-title":"Rinsho Ketsueki"},{"issue":"5","key":"2019111808435200100_B3","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1080\/09537100600746508","article-title":"Reticulated platelets are increased in chronic myeloproliferative disorders, pure erythrocytosis, reactive thrombocytosis and prior to hematopoietic reconstitution after intensive chemotherapy.","volume":"17","author":"Ryningen","year":"2006","journal-title":"Platelets"},{"issue":"1","key":"2019111808435200100_B4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1160\/TH08-03-0186","article-title":"Immature platelets in patients with acute coronary syndromes.","volume":"101","author":"Grove","year":"2009","journal-title":"Thromb Haemost"},{"issue":"1","key":"2019111808435200100_B5","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1365-2141.2004.04987.x","article-title":"Assessment of an immature platelet fraction (IPF) in peripheral thrombocytopenia.","volume":"126","author":"Briggs","year":"2004","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111808435200100_B6","first-page":"930","article-title":"Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy.","volume":"99","author":"Cesari","year":"2008","journal-title":"Thromb Haemost"},{"issue":"10","key":"2019111808435200100_B7","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1182\/blood-2008-06-164087","article-title":"Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera.","volume":"112","author":"Marchetti","year":"2008","journal-title":"Blood"},{"issue":"2","key":"2019111808435200100_B8","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1046\/j.1365-2141.1998.00563.x","article-title":"Flow cytometric analysis of reticulated platelets: evidence for a large proportion of non-specific labelling of dense granules by fluorescent dyes.","volume":"100","author":"Robinson","year":"1998","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111808435200100_B9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-3148.2006.00654.x","article-title":"Immature platelet fraction measurement: a future guide to platelet transfusion requirement after haematopoietic stem cell transplantation.","volume":"16","author":"Briggs","year":"2006","journal-title":"Transfus Med"},{"issue":"4","key":"2019111808435200100_B10","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1182\/blood.V91.4.1288","article-title":"Correlation of thrombosis with increased platelet turnover in thrombocytosis.","volume":"91","author":"Rinder","year":"1998","journal-title":"Blood"},{"issue":"4","key":"2019111808435200100_B11","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0049-3848(02)00131-7","article-title":"Flow cytometric analysis of reticulated platelets in patients with ischemic stroke.","volume":"106","author":"Nakamura","year":"2002","journal-title":"Thromb Res"},{"issue":"4","key":"2019111808435200100_B12","first-page":"804","article-title":"High platelet turnover and reactivity in renal transplant recipients patients.","volume":"104","author":"Cesari","year":"2010","journal-title":"Thromb Haemost"},{"issue":"5","key":"2019111808435200100_B13","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/ajh.21149","article-title":"The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea.","volume":"83","author":"Sirhan","year":"2008","journal-title":"Am J Hematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/9\/2599\/1349211\/zh803511002599.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/9\/2599\/1349211\/zh803511002599.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T14:40:23Z","timestamp":1574088023000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/9\/2599\/29531\/JAK2V617F-mutation-and-hydroxyurea-treatment-as"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,1]]},"references-count":13,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,9,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-02-339655","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,1]]}}}